ProLectin‑M achieves 100% viral elimination by day seven in placebo‑controlled study More: Bioxytran reports rapid viral clearance in phase 2 trial Source: News
read more
Biocodex secures rights to Batten-1 and TX01 in agreement worth up to €173 million More: Thx Pharma and Biocodex sign rare disease licensing deal Source: News
read moreFor months now, all signs have pointed to a looming, steep dropoff in pharmas’ spending on traditional TV advertising. One brand that seems not to have gotten the memo, however, is Johnson & Johnson’s Tremfya. More: J&J’s Tremfya roars into
read moreFollowing a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show. More: GSK, Teva quietly settle Coreg 'skinny label' dispute after
read moreChinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. More: China indicts AstraZeneca and former exec Leon Wang over data, trade charges Source: fierce
read moreGilead is expecting newly launched HIV PrEP Yeztugo to bring in $800 million in 2026 sales, a figure Mizuho Securities analysts described as “probably” conservative. More: Despite tempered sales outlook, Gilead positions Yeztugo to dominate HIV PrEP market as sales
read more© 1994 - 2026 B.M. Pharmaceuticals